Scailyte

Executive Summary

Scailyte is a Swiss TechBio company founded in 2017 that leverages multi-omics data and artificial intelligence to enable precision medicine for autoimmune diseases, with a primary focus on Inflammatory Bowel Disease (IBD). Its proprietary AI platform decodes complex biological signals from multi-omics data to discover novel biomarkers and therapeutic targets, aiming to break the therapeutic ceiling in autoimmunity. Currently in Phase 2/3 clinical development, Scailyte is advancing diagnostic and therapeutic candidates that have the potential to significantly improve patient outcomes. By integrating advanced machine learning with comprehensive molecular profiling, the company addresses the high unmet need in IBD for more effective, personalized treatments. Its Basel-based operations and strong intellectual property position Scailyte as a promising player in the precision medicine landscape.

Upcoming Catalysts (preview)

• Q4 2026Phase 2/3 Interim Data Readout for Lead IBD Program65% success
• Q1 2027FDA Pre-IND or End-of-Phase 2 Meeting for Novel Autoimmune Target60% success
• Q2 2027Strategic Partnership with Major Pharma for Biomarker Platform70% success